Court rules biosimilar 'patent dance' optional, but delays Zarxio
This article was originally published in Scrip
Executive Summary
Amgen might have won the battle, but it didn't win the war in a court fight involving Novartis unit Sandoz's Zarxio (filgrastim-sndz) – the first biosimilar ever approved in the US.